van Puijvelde et al. [43] demonstrated that an orally administrated HSP (acts as TLR 4 agonist) can activate T regulatory (Treg) cells in intestine and blood, resulting in a prevention of atherosclerosis in mice, but a relationship between Treg function and microbiota profiles was not clarified. Here, HSP90B2P is linked to atherosclerosis.